An improved algorithm to screen for carbapenemase production in Pseudomonas aeruginosa
Open Access
- 7 January 2026
- journal article
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 8 (1)
Abstract
Objectives: One of the biggest challenges for healthcare providers is the difficulty with screening for carbapenemase-producing, carbapenem-resistant Pseudomonas aeruginosa (CP-CRPa; P. aeruginosa), given the variety of mechanisms that can mediate carbapenem resistance in P. aeruginosa. We sought to develop an improved algorithm to screen for carbapenemase activity in P. aeruginosa using routine antimicrobial susceptibility testing readily available in most clinical microbiology laboratories. Methods: Antibiograms of a reference set of P. aeruginosa (n = 100) with diverse phenotypic and genotypic profiles were compared to determine which antibiotics optimally screen for and differentiate CP-CRPa from CRPa and non-CRPa. The developed algorithm was then applied to 1482 clinical P. aeruginosa isolates. Carbapenemase PCR and the modified carbapenem inactivation method were performed on all meropenem-resistant P. aeruginosa isolates. Results: The CP-CRPa screening algorithm developed here uses meropenem, ceftazidime and tobramycin. Carbapenem resistance was identified in 85 (5.7%) isolates, of which 26 (1.8%) were confirmed as CP-CRPa. blaGES (57.7%) was the predominant carbapenemase detected, whilst blaNDM, blaVIM, blaIMP and blaKPC carbapenemases were also detected. The CP-CRPa screening algorithm was 100% sensitive (CI95% 84.0%–100%) and 96.6% specific (CI95% 87.3%–99.4%). Conclusions: We present an antimicrobial susceptibility testing-based screening algorithm that uses meropenem, ceftazidime, and tobramycin to screen for CP-CRPa. When appropriate screening criteria are utilized, confirmatory testing can be significantly reduced, resulting in substantial time and resource savings, without compromising sensitivity, particularly in settings with varying carbapenemase epidemiology.Keywords
Funding Information
- NSW Health Pathology
This publication has 38 references indexed in Scilit:
- Characterization of a New Metallo-β-Lactamase Gene, bla NDM-1 , and a Novel Erythromycin Esterase Gene Carried on a Unique Genetic Structure in Klebsiella pneumoniae Sequence Type 14 from IndiaAntimicrobial Agents and Chemotherapy, 2009
- Molecular Epidemiology and Mechanisms of Carbapenem Resistance in Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2009
- In Vitro and In Vivo Activities of a New Cephalosporin, FR264205, against Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2007
- Integrons Containing the VIM-2 Metallo-β-Lactamase Gene among Imipenem-Resistant Pseudomonas aeruginosa Strains from Different Chinese HospitalsJournal of Clinical Microbiology, 2006
- First Detection of the Plasmid-Mediated Class A Carbapenemase KPC-2 in Clinical Isolates of Klebsiella pneumoniae from South AmericaAntimicrobial Agents and Chemotherapy, 2006
- Inter-country transfer of Gram-negative organisms carrying the VIM-4 and OXA-58 carbapenem-hydrolysing enzymesJournal of Antimicrobial Chemotherapy, 2006
- Aminoglycoside Resistance inPseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2005
- Carbapenemase-producingEnterobacteriaceae, U.S. RiversEmerging Infectious Diseases, 2005
- Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa: Our Worst Nightmare?Clinical Infectious Diseases, 2002
- Characterization of Class 1 Integrons from Pseudomonas aeruginosa That Contain the bla VIM-2 Carbapenem-Hydrolyzing β-Lactamase Gene and of Two Novel Aminoglycoside Resistance Gene CassettesAntimicrobial Agents and Chemotherapy, 2001